Figure 4 | Scientific Reports

Figure 4

From: Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

Figure 4

Disease activity scores (DAS) 28 in RA patients stratified on IL-32 promoter SNP and therapy used (etanercept or adalimumab). (A) DAS 28CRP separated on IL-32 promoter SNP genotype and independent of therapy (n = 37 CC vs 85 TT). (B) DAS28CRP separated on IL-32 promoter SNP genotype and Etanercept therapy (n = 13 CC vs 32 TT). (C) DAS28CRP separated on IL-32 promoter SNP genotype and Adalimumab therapy (n = 4 CC vs 13 TT).

Back to article page